Find similar products:
The text only version may be available in large print, Braille or audio CD. For further information call emc accessibility on 0800 198 5000. The product code(s) for this leaflet is: PL 08553/0651.
Deferasirox 90 mg, 180 mg, 360 mg Film-Coated Tablets
Deferasirox 90 mg, 180 mg, 360 mg Film-Coated Tablets
Deferasirox
1. What Deferasirox is and what it is used for
2. What you need to know before you take Deferasirox
3. How to take Deferasirox
4. Possible side effects
5. How to store Deferasirox
6. Contents of the pack and other information
Deferasirox Film-Coated Tablets contain an active substance called deferasirox. It is an iron chelator which is a medicine used to remove the excess iron from the body (also called iron overload). It traps and removes excess iron which is then excreted mainly in the stools.
Repeated blood transfusions may be necessary in patients with various types of anaemia (for example thalassaemia, sickle cell disease or myelodysplastic syndromes (MDS)). However, repeated blood transfusions can cause a build-up of excess iron. This is because blood contains iron and your body does not have a natural way to remove the excess iron you get with your blood transfusions. In patients with non-transfusion-dependent thalassaemia syndromes, iron overload may also develop over time, mainly due to increased absorption of dietary iron in response to low blood cell counts. Over time, the excess iron can damage important organs such as the liver and heart. Medicines called iron chelators are used to remove the excess iron and reduce the risk of it causing organ damage.
Deferasirox is used to treat chronic iron overload caused by frequent blood transfusions in patients with beta thalassaemia major aged 6 years and older.
Deferasirox is also used to treat chronic iron overload when deferoxamine therapy is contraindicated or inadequate in patients with beta thalassaemia major with iron overload caused by infrequent blood transfusions, in patients with other types of anaemias, and in children aged 2 to 5 years.
Deferasirox is also used when deferoxamine therapy is contraindicated or inadequate to treat patients aged 10 years or older who have iron overload associated with their thalassaemia syndromes, but who are not transfusion dependent.
Talk to your doctor or pharmacist before taking Deferasirox:
If any of these apply to you, tell your doctor straight away.
You will have regular blood and urine tests during treatment. These will monitor the amount of iron in your body (blood level of ferritin) to see how well Deferasirox is working. The tests will also monitor your kidney function (blood level of creatinine, presence of protein in the urine) and liver function (blood level of transaminases). Your doctor may require you to undergo a kidney biopsy, if he/she suspects significant kidney damage. You may also have MRI (magnetic resonance imaging) tests to determine the amount of iron in your liver. Your doctor will take these tests into consideration when deciding on the dose of Deferasirox most suitable for you and will also use these tests to decide when you should stop taking Deferasirox.
Your eyesight and hearing will be tested each year during treatment as a precautionary measure.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. This includes in particular:
Additional tests may be required to monitor the blood levels of some of these medicines.
Deferasirox can be used by people aged 65 years and over at the same dose as for other adults. Elderly patients may experience more side effects (in particular diarrhoea) than younger patients. They should be monitored closely by their doctor for side effects that may require a dose adjustment.
Deferasirox can be used in children and adolescents receiving regular blood transfusions aged 2 years and over and in children and adolescents not receiving regular blood transfusions aged 10 years and over. As the patient grows the doctor will adjust the dose.
Deferasirox is not recommended for children aged under 2 years.
If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.
Deferasirox is not recommended during pregnancy unless clearly necessary.
If you are currently using a hormonal contraceptive to prevent pregnancy, you should use an additional or different type of contraception (e.g. condom), as Deferasirox may reduce the effectiveness of hormonal contraceptives.
Breastfeeding is not recommended during treatment with Deferasirox.
If you feel dizzy after taking Deferasirox, do not drive or operate any tools or machines until you are feeling normal again.
Treatment with Deferasirox will be overseen by a doctor who is experienced in the treatment of iron overload caused by blood transfusions.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
The dose of Deferasirox is related to body weight for all patients. Your doctor will calculate the dose you need and tell you how many tablets to take each day.
Deferasirox can also be available as “dispersible” tablets. If you are switching from the dispersible tablets to these film-coated tablets, your dose will change. Your doctor will calculate the dose you need and tell you how many film-coated tablets to take each day.
Taking Deferasirox at the same time each day will also help you remember when to take your tablets.
For patients who are unable to swallow whole tablets, Deferasirox may be crushed and taken by sprinkling the full dose onto soft food such as yogurt or apple sauce (pureed apple). The food should be immediately and completely consumed. Do not store it for future use.
Continue taking Deferasirox every day for as long as your doctor tells you. This is a long-term treatment, possibly lasting for months or years. Your doctor will regularly monitor your condition to check that the treatment is having the desired effect (see also section 2: “Monitoring your Deferasirox treatment”).
If you have questions about how long to take Deferasirox, talk to your doctor.
If you have taken too much Deferasirox, or if someone else accidentally takes your tablets, contact your doctor or hospital for advice straight away. Show the doctor the pack of tablets. Urgent medical treatment may be necessary. You may experience effects such as abdominal pain, diarrhoea, nausea and vomiting and kidney or liver problems that can be serious.
If you miss a dose, take it as soon as you remember on that day. Take your next dose as scheduled. Do not take a double dose on the next day to make up for the forgotten tablet(s).
Do not stop taking Deferasirox unless your doctor tells you to. If you stop taking it, the excess iron will no longer be removed from your body (see also above section “How long to take Deferasirox”).
Like all medicines, this medicine can cause side effects, although not everybody gets them. Most of the side effects are mild to moderate and will generally disappear after a few days to a few weeks of treatment.
These side effects are uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people).
stop taking this medicine and tell your doctor straight away.
These side effects are uncommon:
tell your doctor as soon as possible.
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
If any of these affects you severely, tell your doctor.
Uncommon (may affect up to 1 in 100 people)
If any of these affects you severely, tell your doctor.
Frequency not known (cannot be estimated from the available data).
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme website www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use any pack that is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
The active substance is deferasirox.
The other ingredients are:
Tablet core: crospovidone (E1202); povidone (E1201); cellulose microcrystalline (E460); magnesium stearate (E470b); poloxamer and silica, colloidal anhydrous (E551).
Tablet coating: hypromellose (E464); titanium dioxide (E171); macrogol (E1521); talc (E553b); Indigo carmine aluminium lake (E132).
Deferasirox is supplied as film-coated tablets. The film-coated tablets are ovaloid and biconvex.
Deferasirox 90 mg, 180 mg and 360 mg Film-Coated Tablets are packed in Aluminium-PVC/PE/PVDC blisters.
The blister foil consists of the PVC/PE/PVDC base film sealed against an aluminium lidding foil.
Blisters containing 30 film coated tablets
Blisters containing 90 film-coated tablets
Multipacks containing 300 (10 packs of 30) film-coated tablets.
Not all pack sizes or strengths may be marketed.
This leaflet was last revised in 11/2023.